Longeveron (LGVN) Total Current Liabilities (2021 - 2026)
Longeveron (LGVN) recorded quarterly Total Current Liabilities of $4.3 million in Q1 2026, up 6.31% quarter-over-quarter from $4.1 million in Q4 2025, and up 59.51% on a YoY basis from $2.7 million in Q1 2025.
Longeveron (LGVN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Longeveron's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $4.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 59.51% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 59.51% YoY), while the FY2025 annual figure was $4.1 million, up 58.29% from the prior year.
- Total Current Liabilities was $4.3 million for Q1 2026 at Longeveron, up from $4.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $5.3 million in Q1 2024 to a low of $2.6 million in Q4 2024.
- Historically, Total Current Liabilities has averaged $3.8 million across 5 years, with a median of $3.7 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 79.8% in 2022, then slumped 48.56% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $4.9 million in 2022, then decreased by 20.13% to $3.9 million in 2023, then plunged by 33.61% to $2.6 million in 2024, then soared by 58.29% to $4.1 million in 2025, then advanced by 6.31% to $4.3 million in 2026.
- The last three Total Current Liabilities figures came in at $4.3 million (Q1 2026), $4.1 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 4.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.35 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 5.30 Mn |
| Dec 31, 2023 | 3.89 Mn |
| Sep 30, 2023 | 3.39 Mn |
| Jun 30, 2023 | 4.08 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 4.87 Mn |
| Dec 31, 2021 | 2.71 Mn |